P082: Usefulness of predictive nomograms in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) treated with ketoconazoleRomán Martín A.A., Parra Lopez L., Corchuelo-Maíllo C., Osman-García I., Congregado-Ruiz C.B., Conde-Sánchez J.M., Medina-López R.A.

12 Nov 2015

940

P095: Preferences for the management of androgen deprivation-induced osteoporosis and metabolic syndrome in prostate cancer patients: A European web-based surveyBultijnck R.², Surcel C.³, Ploussard G.⁴, Briganti A.⁵, De Visschere P.⁶, Fütterer J.⁷, Ghadjar P.⁸, Giannarini G.⁹, Isbarn H.¹⁰, Massard C.¹¹, Sooriakumaran P.¹², Van Den Bergh R.¹³, Ost P.¹

12 Nov 2015

825

P103: Evans blue as a diagnostic tool for non-muscle-invasive bladder cancerElsen S.¹, Lerut E.², Van Cleynenbreugel B.³, Van Der Aa F.³, Van Poppel H.³, De Witte P.¹

12 Nov 2015

757

P012: Transparency of pathologic results after radical prostatectomy in the BeneluxFossion L.M.C.L., Vermeulen C.K.M.

12 Nov 2015

14.269

P017: Profile of acute toxicity in prostate cancer with image guided radiotherapy and fiducial markersSalas C., De Ingunza Barón L., Gutiérrez Bayard L., Garduño Sánchez S.

12 Nov 2015

700

P023: Long term Toxicity and quality of life after high-dose-rate brachytherapy as monotherapy for low- and intermediate-risk prostate cancerAluwini S.¹, Busser W.¹, Boormans J.², Kirkels W.², Praag J.¹, Jansen P.¹, Kolkman-Deurloo I-K.¹, Bangma C.²

12 Nov 2015

379

P033: Quality of life of men on active surveillance for prostate cancer versus men without prostate cancer: Are there any differences?Venderbos L.D.F.¹, Korfage I.J.², Roobol M.J.¹

12 Nov 2015

741

P054: Survival after biochemical failure in prostate cancer: Recap database outcomesGonzález-San Segundo C.¹, Jové J.², Zapatero A.², Pastor Peidro J.R.³, Muñoz-Garzón V.⁴, Casaña M.⁵, Mengual J.L.⁶, Gómez-Caamaño A.⁷, Vallejo Ocaña C.⁸, Henriquez I.⁹, Muñoz J.¹⁰, Clemente J.⁶, Porras M.¹¹, Ossola Lentati G.¹², Collado Ballesteros E.¹³, Villafranca Iturre E.¹⁴, Cabeza Rodríguez A.¹⁵

12 Nov 2015

391

P063: Long term clinical outcomes and toxicity of salvage radiotherapy after radical prostatectomy for prostate cancer patientsAluwini S.¹, Van Dessel L.², Sarah R.¹, Bangma C.¹, Jansen P. P.³

12 Nov 2015

330

P071: Testosterone suppression with an innovative form of leuprorelin acetate as solid biodegradable implant in patients with advanced prostate cancer. Results from four trials and comparison with traditional leuprorelin acetate microcapsules formulationSolarić M.², Bjartell A.³, Thyroff-Friesinger U.⁴, Meani D.¹

12 Nov 2015

356

P073: Phase 1b study of ARN-509 with abiraterone acetate and prednisone in patients with metastatic Castration-Resistant Prostate Cancer (mCRPC)Posadas E.¹, Chi K.N.², De Wit R.³, De Jonge M.J.A.³, Attard G.⁴, Friedlander T.⁵, Yu M.K.⁶, Hellemans P.⁷, Chien C.⁸, Abrams C.⁹, Gonzalez M.¹⁰, Trudel G.C.⁶, Chauhan V.¹¹, Jiao J.¹¹, Saad F.¹²

12 Nov 2015

322

EP168: Evaluation of chemotherapy response in seminomasCosta A.L.¹, Abreu C.¹, Pacheco T.¹, Ortega A.², Mulet N.², Jimenez L.², Piulats J.M.², Quintela A.¹, Costa L.¹, Garcia Del Muro X.²

12 Nov 2015

336

EP168:

12 Nov 2015

329

EP177: Tumour size in MRI and percentage of cancer in biopsy are independent predictors of side-specific pathologic T3 prostate cancerDybowski B.¹, Bres-Niewada E.¹, Lorenc T.², Powała A.³, Borkowski T.¹, Radziszewski P.¹

12 Nov 2015

402

P143: Treatment of renal cell carcinoma of native kidney in kidney transplantationLedo Cepero M.J., Parra Servan P., Ojeda A.V., León Delgado C., Rosety Rodriguez J., Amores Bermúdez J., Cañete Bermúdez J., Pérez-Lanzac A., Alvarez-Ossorio Fernández J.L

12 Nov 2015

253

P150: Radical nephrectomy vs partial nephrectomy in patients with localized renal cell carcinoma and normal contralateral kidneyVolkova M.I.¹, Skvortcov I.Ya.², Chernyaev V.A.¹, Klimov A.V.¹, Kalinin S.A.¹, Peters M.V.², Matveev V.B.¹

12 Nov 2015

303

P152: Prognostic factors of perioperative outcomes of RCC patients with IVC thrombosisMatveev V.¹, Volkova M.I.¹, Feoktistov P.I.², Zguzgginova O.V.³, Nekhaev I.V.³, Lomidze S.V.³, Klimov A.V.¹, Kalinin S.A.¹

12 Nov 2015

346

P158: Do real-world outpatient patients resemble the population selected in a clinical trial?Abreu C., Costa A.L., Pacheco T., Quintela A., Costa L.

12 Nov 2015

311

P109: Variations in pelvic lymph node dissection in clinical stage I-III bladder cancer: A Dutch nationwide population-based studyHermans T.J.N.¹, Fossion L.M.C.L.², Van Rhijn B.W.G.¹, Fransen Van De Putte E.E.¹, Verhoeven R.H.A.³, Horenblas S.¹

12 Nov 2015

340

P046: A Phase 3 study of enzalutamide in non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) patientsHeidenreich A.¹, Sternberg C.N.², Fizazi K.³, Saad F.⁴, Shore N.⁵, Hirmand M.⁶, Van Os S.⁷, Akella L.⁸, Modelska K.⁹, Hussain M.¹⁰

12 Nov 2015

388

P117: Prescribing platinum chemotherapy based on glomerular filtration rate using wright formula instead of nuclear medicine radioactive technetium-99m for transitional cell carcinoma of bladderSundaramurthy A., Malik J.M., Mclaren D.B., Law A.B.

12 Nov 2015

335

P125: Clinical significance of Topoisomerase II, Ki-67 and P53 expression in non-muscle invasive urothelial carcinomaElkhouly E.A.¹, Elkady N.², Sultan M.³

12 Nov 2015

323

P131: Patterns of failure and predictors of recurrence for urothelial bladder cancer after radical cystectomyAli A.M., Abulkassem H., Shawky A.

12 Nov 2015

339

P163: Does bilateral testicular germ cell tumours have worse prognostic features? Single tertiary referral center experienceAkdoğan B., Citamak B., Altan M., Özen H.

12 Nov 2015

267

EP169: MpMRI-Histopathologic correlation of normal, benign and malignant conditions of the prostateDe Visschere P.¹, Vral A.², Perletti G.³, Pattyn E.¹, Villeirs G.¹

12 Nov 2015

301